Safety, pharmacokinetics, and antiviral activity of RO7049389, an allosteric core protein modulator, in patients with chronic hepatitis B virus infection: a multicenter, randomized, placebo-controlled phase 1 study - The Lancet
Nuclear Regulation

Safety, pharmacokinetics, and antiviral activity of RO7049389, an allosteric core protein modulator, in patients with chronic hepatitis B virus infection: a multicenter, randomized, placebo-controlled phase 1 study – The Lancet

By Carmen Lillard

Safety, pharmacokinetics, and antiviral activity of RO7049389, an allosteric core protein modulator, in patients with chronic hepatitis B virus infection: a multicenter, randomized, placebo-controlled phase 1 study, The Lancet

Carmen Lillard 11096 posts 0 comments
You might also like More from author

Comments are closed.